Alumis Inc. ALMS
4.84 USD -0.30 (-5.84%)
Regular-session close
4.84 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
4.70 Day range 5.13
4.70 52-week range 31.35
- YTD
- -50.41%
- 1 year
- -13.11%
News
benzinga.com Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $28 Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $37 to $28.
benzinga.com Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $18 Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $25 to $18.
benzinga.com HC Wainwright & Co. Maintains Buy on Alumis, Lowers Price Target to $9 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Alumis (NASDAQ:ALMS) with a Buy and lowers the price target from $15 to $9.
globenewswire.com Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48…
defenseworld.net Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages Shares of Alumis Inc. (NASDAQ: ALMS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, Marketbeat.com reports.…
defenseworld.net Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One…
globenewswire.com Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures – Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis –…
defenseworld.net Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
defenseworld.net Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
defenseworld.net Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS) Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies…
seekingalpha.com Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net 226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the…
globenewswire.com Alumis to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with…
seekingalpha.com Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The…
seekingalpha.com Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
marketbeat.com Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population.…
reuters.com Alumis eyes late-stage lupus study despite trial miss Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a…
globenewswire.com Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) – LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature…
globenewswire.com Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
defenseworld.net California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities…
zacks.com 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
benzinga.com Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin…
defenseworld.net Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next? Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline…
